Hydrocortisone autoinjector - Crossject
Alternative Names: Needleless hydrocortisone autoinjector; ZENEO - Crossect; ZENEO® Hydrocortisone; ZENEO® Hydrocortisone Autoinjector; ZENEO® needleless deviceLatest Information Update: 28 Dec 2025
At a glance
- Originator Crossject
- Class Alcohols; Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Yes - Adrenal insufficiency
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Adrenal insufficiency
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for clinical-Phase-Unknown development in Adrenal-insufficiency in USA
- 27 Mar 2025 Eton Pharmaceuticals announces intention to submit NDA to US FDA and EMA for Adrenal insufficiency in second half of 2026
- 09 Dec 2024 Crossject re-establishes CRADA with Department of Defense for the development of ZENEO autoinjector